TATAA Strengthens Quality Assurance Program
News May 21, 2013
TATAA Biocenter is strengthening its quality assurance program by introducing RNA quality assessment using Advanced Analytical Technologies, Inc. (“AATI”) Fragment Analyzer™ into its company’s Standard Operating Procedures (SOPs) for expression profiling. “As we are analysing more and more complex samples, including preserved materials such as formalin fixed and paraffin embedded tissues, soils and sewer samples, and other aggressive matrices, the quality of the extracted nucleic acids becomes critical for meaningful analysis. Much money can be saved by identifying problems at an early stage and either discarding poor quality samples or replacing them. With the Fragment Analyzer™ we can do this in high throughput, at acceptable cost and with greatest confidence”, says Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.
Since the Fragment Analyzer™ product launch in early 2012, AATI has placed over 275 units worldwide and has quickly become the technology solution standard to which all others are measured within the rapidly expanding nucleic acids analysis industry.
“We couldn’t be more pleased to have an organization with the creditability of TATAA Biocenter added to our customer list. The Fragment Analyzer™ was designed and built with end-users first in mind,” said Dr. Steven Lasky, founder and CEO of AATI. “When we speak with potential users of the Fragment Analyzer™ we hear the same problem, they are frustrated with the existing competitive solutions; lack of ability to scale with their throughput, lack of reproducible resolution and lack of ability to perform multiple assessments on a single machine. Our proprietary technology allows us to streamline sample processing steps, analyze PCR and NGS library DNA fragments, total and messenger RNA, genomic DNA and DNA mutation detection assays all under one foot print. Together these attributes facilitate an enhanced return on capital for our customers.”
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE